Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Actuate Therapeutics IncNASDAQ: ACTU
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $1.36M rose 20.6% year over year, behind the +111.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 12.0% from the prior quarter. Over 3 fiscal years it compounded at +109.9% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +20.6% toward the trailing-twelve-month pace of +111.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.05M USD
- Year-over-year change
- +203.0%
- 3-year CAGR
- +109.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.05M | +203.0% |
| FY2024 | 2024-12-31 | 2M | +371.2% |
| FY2023 | 2023-12-31 | 423.54K | -35.2% |
| FY2022 | 2022-12-31 | 654.07K | — |
Stock-Based Compensation vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +111.2% is the 2nd highest of 9, against a peer median of -32.7%.
- Over three fiscal years its annual growth of +109.9% compares with a peer median of -10.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $27.69M USD | +218.3% | +20.9% | — | |
| LTM Mar 2026 | $21.22M USD | -43.4% | -16.7% | 115.2% | |
| LTM Mar 2026 | $10.03M USD | -22.0% | +30.6% | — | |
| LTM Mar 2026 | $9.79M USD | -43.4% | -24.8% | 853.3% | |
| LTM Mar 2026 | $7.62M USD | -49.8% | -20.2% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $6.28M USD | +111.2% | +109.9% | — |
| LTM Mar 2026 | CHF 4.21M CHF | -4.1% | -4.6% | — | |
| LTM Mar 2026 | $3.88M USD | -47.0% | -22.0% | 7.1% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $3.05M USD | +83.8% | +67.0% | — |
| Peer median (excluding ACTU) | — | -32.7% | -10.7% | 115.2% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (20.16M) | (24.74M) | (27.29M) | (22.23M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 654.07K | 423.54K | 2M | 6.05M |
| Change in Working Capital | 1.73M | 2.57M | 1.1M | (3.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 586.26K | 1.29M | (1.5M) | (512.54K) |
| Other Working Capital | 1.15M | 1.28M | 2.6M | (2.53M) |
| Other Non-Cash Items | (20.38K) | 123.46K | 2.35M | 20.25K |
| Operating Cash Flow | (17.79M) | (21.63M) | (21.84M) | (19.21M) |
| Capital Expenditures | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 5.5M | 0 |
| Common Stock Issued | 0 | 0 | 23.96M | 24.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (1.93M) | (302.83K) |
| Financing Cash Flow | 19.26M | 4.13M | 27.53M | 23.72M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.46M | (17.49M) | 5.68M | 4.52M |
| Free Cash Flow | (17.79M) | (21.63M) | (21.84M) | (19.21M) |
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.